U.S. markets closed
  • S&P 500

    +73.47 (+1.95%)
  • Dow 30

    +572.16 (+1.85%)
  • Nasdaq

    +196.68 (+1.55%)
  • Russell 2000

    +45.29 (+2.11%)
  • Crude Oil

    +2.45 (+3.84%)
  • Gold

    -2.50 (-0.15%)
  • Silver

    -0.17 (-0.65%)

    -0.0054 (-0.45%)
  • 10-Yr Bond

    +0.0040 (+0.26%)

    -0.0067 (-0.48%)

    +0.2690 (+0.25%)

    -704.34 (-1.45%)
  • CMC Crypto 200

    +39.75 (+4.21%)
  • FTSE 100

    -20.36 (-0.31%)
  • Nikkei 225

    -65.78 (-0.23%)

Veracyte Announces Initiation of Consensus Study Exploring Medical Utility of Multiple Breast Cancer Genomic Tests

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

PROCURE study will capture insights from 180 European breast cancer specialists, to develop consensus and recommendations

Veracyte, Inc. (Nasdaq: VCYT) announced today the initiation of a European study that will utilize the Delphi methodology to generate consensus regarding the clinical utility of genomic tests in breast cancer treatment. Led by an independent scientific committee of breast cancer experts with input from 180 breast cancer clinicians practicing in 12 European countries, the PROCURE study will explore and achieve consensus on the evidence supporting the most frequently used breast cancer multigene signatures (i.e., genomic tests).

"As we’ve continued to learn more about how genomics impact treatment response and outcomes in breast cancer patients, genomic tests have become an invaluable tool for physicians," said Giuseppe Curigliano, MD, PhD, Istituto Europeo di Oncologia, Milan, and the PROCURE study coordinator. "However, there is not yet any consensus in the breast cancer community regarding the utility and ideal application of available tests, and this significantly complicates decision making. I’m excited to lead this study, which will generate this consensus using real-world insights and experiences from leading clinicians across Europe."

The Delphi method is a survey technique and established methodology for facilitating consensus on complex issues. The process includes at least two rounds of a structured questionnaire containing items to which participants express their degree of agreement. Consensus is reached by grouping participants’ responses after each successive wave of questioning. The PROCURE study will be conducted by Adelphi Targis, a medical research, education and communication agency with extensive experience using the Delphi methodology, and guided by an independent scientific committee led by Dr. Curigliano.

Over approximately 12 months, the study will gather input from participants to:

  • Comprehensively evaluate the existing evidence supporting the use of breast cancer genomic tests and the added value that clinicians attribute to them.

  • Assess the current and optimized use of these tools in patients with differing clinical-pathological profiles.

  • Establish recommendations on their use in routine clinical practice.

  • Discuss future clinical applications and research opportunities to facilitate a precision medicine approach in breast cancer.

Applying the rigorous Delphi process, the PROCURE scientific committee will use published clinical evidence along with participants’ input to establish and publish consensus recommendations for the use of genomic tests in clinical practice.

"PROCURE will provide much-needed guidance to breast cancer clinicians and their patients, helping them fully access the benefits offered by genomic testing," said Bonnie Anderson, Veracyte’s chairman and chief executive officer. "We’re grateful for the opportunity to sponsor this important study and to demonstrate our commitment to the global breast cancer community."

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the PROCURE study. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. Factors that may impact these forward-looking statements can be found in Item 1A – "Risk Factors" in our Annual Report on Form 10-K filed with the SEC on February 25, 2020 and in our Quarterly Report on Form 10-Q filed with the SEC on July 30, 2020. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, Afirma, Percepta, Envisia, Prosigna, LymphMark, and the Veracyte logo are trademarks of Veracyte, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200911005088/en/


Investor and Media Contact:
Tracy Morris